Quick Takeaways
- BIOGEN INC. filed SCHEDULE 13D for APELLIS PHARMACEUTICALS, INC. Common Stock, par value $0.0001 per share (APLS).
- Disclosed ownership: 14%.
- Date of event: 31 Mar 2026.
BIOGEN INC. - 31 Mar 2026 SCHEDULE 13D Report for APELLIS PHARMACEUTICALS, INC. Common Stock, par value $0.0001 per share (APLS)
- Filing Manager
- BIOGEN INC.
- Reporting Manager
- BIOGEN INC.
- Symbol
- APLS
- Shares outstanding
- 130,066,725 shares
- Disclosed Ownership
- 18,469,475 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13D
- Filing time
- 06 Apr 2026, 18:08:10 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"BIOGEN INC. disclosed 14% ownership in APELLIS PHARMACEUTICALS, INC. Common Stock, par value $0.0001 per share (APLS) on 31 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 Apr 2026, 18:08.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOGEN INC. | 14% | 18,469,475 | 0 | 18,469,475 | /s/ Wendell Taylor | Wendell Taylor / Secretary | 0000875045 |